New vision for preventing & curing age-related diseases, James Peyer, Founder & CEO, Cambrian Bio

New vision for preventing & curing age-related diseases, James Peyer, Founder & CEO, Cambrian Bio

Synopsis: James Peyer, Ph.D., is the Founder and CEO of Cambrian Bio, a clinical-stage drug-development company focused on creating therapies to prevent and cure age-related diseases. James discusses the driving force behind his interest in aging biology and oncology, how his perspective on aging has changed over the years, his entrepreneurial journey, and what he hopes to achieve over the next decade with PipeCos such as Telos, Amplifier, and Tornado. He also discusses the inherent risk involved in drug development, how he manages the emotional aspects, and Cambrian’s vision for the future of drug development. Biography: James Peyer is the Chief Executive Officer and Founder of Cambrian Bio. He also holds multiple board and executive roles across Cambrian’s pipeline. He has spent his entire life dedicated to the mission of finding ways of preventing people from getting diseases like cancer and Alzheimer’s instead of waiting for people to get sick. James was previously Founder and Managing Partner at Apollo Ventures, the first global longevity-focused venture capital firm, investing across the US and Europe. Prior to Apollo, James was a biotech R&D specialist at the New York office of McKinsey & Company, serving major pharmaceutical clients. He earned his PhD in stem cell biology at University of Texas Southwestern Medical Center as a National Science Foundation Fellow and received his B.A. with special honors from the University of Chicago. Interested to learn more: Telos: https://www.telosbio.com/ Amplifier: https://www.amplifier-tx.com/ Tornado: https://www.tornado-tx.com/

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(263)

Nick Myerberg, Partner & Head of AI at Braidwell on AI's Next Era in Drug Discovery

Nick Myerberg, Partner & Head of AI at Braidwell on AI's Next Era in Drug Discovery

Synopsis: The guest on today's podcast is a representative of Braidwell LP, a registered investment adviser. Braidwell invests on behalf of its clients and either holds, or may in the future hold, p...

3 Elo 47min

Robert Jacks, CEO of Sparrow Pharmaceuticals | Precision Medicine, Biotech Strategy & Leadership

Robert Jacks, CEO of Sparrow Pharmaceuticals | Precision Medicine, Biotech Strategy & Leadership

Synopsis: In an industry often defined by rapid innovation and high-stakes science, long-term success in biotech requires more than breakthrough discoveries—it demands strategic clarity, resilient l...

22 Heinä 34min

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Synopsis: While biotech is increasingly measured by clinical milestones and financial outcomes, Rahul Chaturvedi welcomes two leaders who argue that true success begins and ends with patients. In th...

10 Kesä 41min

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically...

13 Touko 33min

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Co...

16 Huhti 23min

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Synopsis: Addiction is often misunderstood as a failure of willpower—but emerging science increasingly shows it may be deeply rooted in biology. In this episode of Biotech 2050, recorded during JPM...

6 Maalis 14min

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Synopsis: This episode is proudly sponsored by Quartzy. Physician-scientist, biotech founder, and leadership advocate Sheila Gujrathi, MD joins Rahul Chaturvedi on the Biotech 2050 Podcast for a po...

5 Maalis 39min

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Synopsis: At the heart of JPM 2026’s biotech buzz, Alok Tayi sits down with Fred Aslan, CEO of Artiva, to explore how bold platform bets, scalable cell therapies, and autoimmune breakthroughs could ...

11 Helmi 25min

Suosittua kategoriassa Tiede

rss-poliisin-mieli
tiedekulma-podcast
utelias-mieli
rss-mita-tulisi-tietaa
docemilia
rss-duodecim-lehti
rss-tiedetta-vai-tarinaa
rss-luontopodi-samuel-glassar-tutkii-luonnon-ihmeita
rss-ammamafia
rss-bios-podcast
rss-astetta-parempi-elama-podcast
rss-hereilla
sotataidon-ytimessa
ihanat-ipanat
mielipaivakirja
rss-tervetta-skeptisyytta